# Progress Note 06 — Preventive Visit

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Jacqueline du Pré (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML039-SYN
- Date: 2026-09-14
- Fictional facility: St. Posthumous Health Center
- Fictional author: Imogen Thackeray-Osei, MD
- Calendar frame: modern shifted

- Visit type: Preventive Visit
- Services: CPT 99395 (periodic preventive medicine, established patient, age 18 to 39) with CPT 99497 (advance care planning) on the same day

## Chief complaint

Periodic adult preventive visit. **S**

## History of present illness

Ms. du Pré, 28, comes for her yearly preventive visit five months after starting ocrelizumab. She has had no relapse; the cystitis in June cleared with nitrofurantoin and the tingling that came with it went within two days. She practices three to four hours a day, played chamber music in public last month for the first time this year, and teaches two students a week. Fatigue comes in the late afternoon and she plans her day around it. She takes cholecalciferol 4000 units daily. Her PHQ-9 today is 3. **S**

| Element | Detail |
|---|---|
| Visit | Periodic adult preventive visit, age 28 |
| Active conditions | Relapsing-remitting multiple sclerosis on ocrelizumab; vitamin D deficiency on replacement |
| Medicines | Ocrelizumab every six months (next dose next month); cholecalciferol 4000 units daily |
| Mood | PHQ-9 3 |

## Health risk assessment

Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Thackeray-Osei. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Good, and much better than in the spring |
| Psychosocial | Busy with practice, teaching and concerts; worries about another relapse; good support from friends |
| Tobacco | Never smoked |
| Alcohol and drugs | A glass of wine two or three evenings a week; no drugs |
| Physical activity | Swims twice a week and walks daily, as the occupational therapist suggested for fatigue |
| Nutrition | Regular meals; no restrictions |
| Sleep | Eight hours; rests for half an hour after lunch |
| Sexual and reproductive health | Condoms used consistently; not planning a pregnancy this year |
| Safety at home | Feels safe; no one hurts, threatens or controls her |
| Road safety | Wears a seat belt; does not drive when tired |
| Activities of daily living | Independent |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Positive | Late-afternoon fatigue, managed with pacing; no fever or weight loss |
| Eyes | Negative | No blurred vision or pain on moving the eyes |
| Ears, nose, mouth, and throat | Negative | No hearing change |
| Cardiovascular | Negative | No chest pain or palpitations |
| Respiratory | Negative | No cough or breathlessness |
| Gastrointestinal | Negative | Bowels regular |
| Genitourinary | Negative | No urgency or burning since June |
| Breast | Negative | No lump |
| Musculoskeletal | Negative | Some neck and shoulder stiffness after long practice |
| Integumentary | Negative | No rash or changing moles |
| Neurological | Positive | Faint tingling in the left fingertips after long practice; no weakness or imbalance |
| Psychiatric | Negative | Mood good; PHQ-9 3; no thoughts of self-harm |

12 systems reviewed. **S**

## Current medications

- Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth daily **S**
- Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion **S**

## Allergies

- No known allergy **S**

## Objective

BP 110/70 mmHg; pulse 68 bpm; respirations 14/min; temperature 36.6 °C; oxygen saturation 99% on room air; weight 63.9 kg; BMI 21.4 kg/m². All vital signs are synthetic.

PHQ-9: 3. All results are synthetic.

## Immunizations given today

- Influenza vaccine, this season (inactivated) **S**
- COVID-19 mRNA vaccine, this season's formula **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Well; weight 63.9 kg, BMI 21.4; blood pressure 110/70 |
| Head, eyes, ears, nose, and throat | Normal; fundi normal |
| Neck | No lymph nodes; thyroid normal |
| Breasts | Examined with her agreement and a chaperone: no mass or nipple discharge; no axillary nodes |
| Cardiovascular | Regular rhythm; no murmur |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft, non-tender |
| Skin | No rash; no suspicious moles |
| Musculoskeletal | Tight upper trapezius muscles; full neck movement |
| Neurological | Vibration slightly reduced in the left fingertips only; strength, reflexes and gait normal |
| Psychiatric | Bright, warm and engaged |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Periodic adult preventive visit completed**. Health risk assessment reviewed and the prevention plan updated for a woman of 28 on B-cell therapy for multiple sclerosis. Inactivated influenza and COVID-19 vaccines given today; responses may be reduced while B cells are depleted, but the vaccines still protect and are recommended. Live vaccines are avoided on ocrelizumab; she is immune to measles and varicella. Pneumococcal and recombinant zoster vaccines were completed before and during treatment. The hepatitis B surface antibody check after her two hepatitis B doses has not yet been drawn and will be done with next month's blood tests. Cervical screening is up to date. Contraception was discussed again: she uses condoms consistently and was offered an IUD or implant for more reliable protection during treatment; she will consider it. **S**
   - Influenza and COVID-19 vaccines given today.
   - Hepatitis B surface antibody with the blood tests before the next ocrelizumab dose.
   - Cervical screening next year.
   - Stretching and posture work for neck and shoulder strain from practice.
   - Next preventive visit in one year.
2. **Relapsing-remitting multiple sclerosis on ocrelizumab** (G35.A). No relapse since starting treatment; the re-baseline MRI two months ago showed no new or enhancing lesions. **S**
   - Ocrelizumab 600 mg next month, with blood count, immunoglobulins and a pregnancy test beforehand.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Blood pressure screening | Completed today | 110/70 mmHg |
| Depression screening | Completed today | PHQ-9 score 3; item 9 scored 0 |
| Unhealthy alcohol use screening | Completed today | Two or three glasses of wine a week; low risk |
| Tobacco use | Completed today | Never smoked |
| Intimate partner violence screening | Completed today | Negative; she feels safe |
| Cervical cancer screening | Up to date | Cytology two years ago normal; next at three years |
| Chlamydia and gonorrhea screening | Not indicated | Over 24 and not at increased risk |
| HIV, hepatitis B and hepatitis C screening | Up to date | All negative before treatment |
| Influenza vaccine | Completed today | Inactivated vaccine, about five weeks before the next ocrelizumab dose |
| COVID-19 vaccine | Completed today | This season's mRNA vaccine |
| Pneumococcal vaccine | Up to date | PCV20 before treatment, for an adult starting immunosuppressive therapy |
| Recombinant zoster vaccine | Up to date | Two doses, before and during treatment |
| Hepatitis B vaccine | Due | Two doses given; the surface antibody check after the series is due with next month's blood tests |
| HPV vaccine | Up to date | Series completed in adolescence |
| Tetanus, diphtheria, and pertussis | Up to date | Tdap three years ago |
| Live vaccines (MMR, varicella) | Not indicated | Immune to measles and varicella; live vaccines are avoided on ocrelizumab |
| Contraception counseling | Completed today | Condoms used consistently; IUD or implant offered for more reliable protection during treatment |
| Dental and vision examination | Due | Dental check due; eye examination normal today on fundoscopy, optometry yearly |

## Advance care planning

Voluntary advance care planning discussion of about 15 minutes, with her consent. She named a health care agent, recorded in the confidential part of the chart and not named here. She said that she wants to be told plainly about her illness and its treatment, that she wants every treatment that can keep her playing and independent, and that if she were ever too ill to decide she would want her wishes about music and comfort respected. To be revisited at each change in her health and at least yearly. **S**

## Guideline basis

- Farez MF, et al. Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis. Neurology 2019;93(13):584-594 (PMID 31462584) (2019), American Academy of Neurology
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge
- USPSTF A and B Recommendations (2026), U.S. Preventive Services Task Force
- Cervical Cancer: Screening (2018), U.S. Preventive Services Task Force
- Adult Immunization Schedule by Medical Condition and Other Indication (2026), Centers for Disease Control and Prevention

## Follow-up

- Ocrelizumab 600 mg next month with blood tests and hepatitis B surface antibody beforehand. Cervical screening next year. Next preventive visit in one year. **S**
- Next scheduled visit 2026-10-12: six months: first 600 mg dose of ocrelizumab, no evidence of disease activity, immunoglobulins, vaccination response, pregnancy planning and her return to performing. **S**
